Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardent Health, Inc. filings document the formal reporting record for a public healthcare provider operating acute care hospitals and related sites of care through subsidiaries. Form 8-K disclosures furnish quarterly operating results, including revenue, admissions measures, net patient service revenue, adjusted EBITDA, and related non-GAAP reconciliations.
The filing record also covers governance and capital-structure matters. Proxy materials describe annual-meeting proposals, director elections, executive compensation, equity awards, and pay-versus-performance data. Other 8-K filings report executive-separation and severance arrangements, a common stock repurchase authorization, and amendments to term loan and asset-based lending credit agreements involving subsidiary borrowers and guarantors.
Ardent Health, Inc. director Robert DeMichiei reported an open-market purchase of Common Stock. He bought 11,260 shares at a weighted average price of $8.73 per share, increasing his direct holdings to 35,564 shares. The trade was executed through multiple transactions on June 5, 2026 at prices between $8.60 and $8.78.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine made an open-market purchase of 10,000 shares of Common Stock at $8.81 per share. After this transaction, he directly owns 329,183 shares, increasing his personal stake in the company.
Ardent Health, Inc. appointed former Chief Operating Officer Dave Caspers as President and Chief Executive Officer and to its Board, effective June 2, 2026, succeeding Marty Bonick, who has separated from the company and stepped down from the Board.
Ardent entered into a new employment agreement with Mr. Caspers that runs initially through May 31, 2029 and provides a base salary of $900,000, a target annual bonus opportunity of 105% of base salary for 2026, eligibility for equity awards under the 2024 Omnibus Incentive Award Plan, and standard executive benefits.
If he is terminated without cause or resigns for good reason, Mr. Caspers is eligible for cash severance equal to two times salary plus target bonus and up to 18 months of continued health benefits, increasing to three times salary plus target bonus for qualifying terminations around a change in control. He is also subject to a 24‑month post-employment non‑competition and non‑solicitation covenant.
In an accompanying press release, Ardent highlighted Mr. Caspers’ operational background at Walmart Health, Banner Health, Target, and Leslie’s and noted his leadership of the company’s IMPACT margin-improvement program. The company reported volume softness in the second quarter but reaffirmed its full‑year 2026 Adjusted EBITDA guidance of $485 million to $535 million.
Ardent Health, Inc. reported the results of its Annual Meeting of Stockholders held on May 20, 2026. Stockholders representing 98,778,826 shares of common stock were present in person or by proxy, out of 143,095,662 shares outstanding and entitled to vote as of the record date.
All 11 director nominees were elected, each receiving more votes "For" than "Withhold." Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, they ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Ardent Health, Inc. reported first quarter 2026 results showing solid top-line and profit growth. Total revenue rose 7.0% year-over-year to $1.60 billion, driven by a 2.0% increase in adjusted admissions and a 5.5% increase in net patient service revenue per adjusted admission.
Net income attributable to Ardent Health was $39.9 million, or $0.28 per diluted share, compared with $41.4 million, or $0.29, a year earlier as margin mix and non-operating items shifted. Adjusted EBITDA increased 26.3% to $124 million, and excluding a $10.9 million investment gain, grew 15%.
Operationally, total surgeries grew 1.2% while admissions declined 1.1%, reflecting severe weather and a lighter respiratory season. As of March 31, 2026, Ardent held $610 million of cash, $1.1 billion of total debt, and a lease-adjusted net leverage ratio of 2.6x, improved from 3.0x a year earlier. The company reaffirmed full-year 2026 guidance, including total revenue of $6.4–$6.7 billion and Adjusted EBITDA of $485–$535 million.
Ardent Health, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on May 20, 2026. Holders of 143,095,662 outstanding common shares as of March 26, 2026 may vote.
Stockholders will elect 11 directors, approve on a non-binding basis executive pay, and ratify Ernst & Young LLP as auditor for 2026. Ardent is a controlled company, with EGI‑AM owning about 54% of the voting power and Pure Health about 21.1%. The proxy describes committee structures, director independence determinations, and a compensation program focused on base salary, annual cash incentives, and performance-based equity. For 2025, revenue was $6.3 billion with 6% growth, adjusted EBITDA rose 9%, and operating cash flow reached $471 million, supporting pay decisions and performance-based awards.
Ardent Health, Inc. director Peter J. Bulgarelli reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units at no cash exercise price. Following this award, he holds 14,231 shares directly. The units vest in full on the first anniversary of April 1, 2026, conditioned on his continued service with the company through that vesting date.
Havdala Ellen reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Ellen Havdala reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units. These units will vest in full on the first anniversary of April 1, 2026, as long as she continues serving the company through that date. After this grant, she holds 115,367 shares of common stock directly.